12 West Capital Management LP Trims Holdings in Maravai LifeSciences Holdings, Inc. $MRVI

12 West Capital Management LP lowered its stake in shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) by 28.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 8,921,335 shares of the company’s stock after selling 3,600,000 shares during the period. Maravai LifeSciences accounts for about 3.5% of 12 West Capital Management LP’s investment portfolio, making the stock its 9th largest position. 12 West Capital Management LP’s holdings in Maravai LifeSciences were worth $28,994,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently modified their holdings of the company. Monaco Asset Management SAM grew its holdings in shares of Maravai LifeSciences by 315.0% in the third quarter. Monaco Asset Management SAM now owns 3,656,337 shares of the company’s stock valued at $10,494,000 after purchasing an additional 2,775,372 shares in the last quarter. Brummer Multi Strategy AB purchased a new position in shares of Maravai LifeSciences in the fourth quarter valued at $1,488,000. First Eagle Investment Management LLC purchased a new position in shares of Maravai LifeSciences in the third quarter valued at $1,294,000. Royce & Associates LP grew its holdings in shares of Maravai LifeSciences by 38.0% in the third quarter. Royce & Associates LP now owns 1,761,764 shares of the company’s stock valued at $5,056,000 after purchasing an additional 484,908 shares in the last quarter. Finally, Tejara Capital Ltd grew its holdings in shares of Maravai LifeSciences by 23.1% in the fourth quarter. Tejara Capital Ltd now owns 3,020,209 shares of the company’s stock valued at $9,816,000 after purchasing an additional 566,768 shares in the last quarter. Institutional investors own 50.25% of the company’s stock.

Insiders Place Their Bets

In related news, General Counsel Kurt Oreshack sold 25,000 shares of the company’s stock in a transaction dated Tuesday, June 9th. The shares were sold at an average price of $5.06, for a total value of $126,500.00. Following the completion of the sale, the general counsel directly owned 360,767 shares of the company’s stock, valued at $1,825,481.02. This represents a 6.48% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 2.49% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

MRVI has been the subject of a number of recent research reports. Wall Street Zen raised shares of Maravai LifeSciences from a “hold” rating to a “buy” rating in a report on Saturday, May 23rd. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and issued a $6.00 target price on shares of Maravai LifeSciences in a report on Friday, May 8th. Wells Fargo & Company lifted their price objective on shares of Maravai LifeSciences from $4.50 to $5.50 and gave the stock an “overweight” rating in a research note on Friday, May 8th. Weiss Ratings raised shares of Maravai LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, May 29th. Finally, UBS Group reaffirmed a “reduce” rating on shares of Maravai LifeSciences in a research note on Wednesday, June 3rd. Three analysts have rated the stock with a Buy rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $5.50.

Maravai LifeSciences Stock Up 4.2%

Shares of MRVI opened at $5.22 on Thursday. The firm has a market capitalization of $1.35 billion, a P/E ratio of -7.35 and a beta of 0.72. Maravai LifeSciences Holdings, Inc. has a 12-month low of $1.99 and a 12-month high of $5.32. The company has a current ratio of 5.91, a quick ratio of 4.96 and a debt-to-equity ratio of 0.72. The firm has a fifty day moving average price of $4.18 and a 200-day moving average price of $3.67.

Maravai LifeSciences (NASDAQ:MRVI) last issued its earnings results on Thursday, May 7th. The company reported $0.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.06. Maravai LifeSciences had a negative net margin of 51.07% and a negative return on equity of 17.87%. The firm had revenue of $65.84 million during the quarter, compared to analyst estimates of $53.00 million. Equities research analysts expect that Maravai LifeSciences Holdings, Inc. will post -0.2 earnings per share for the current year.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc (NASDAQ: MRVI) is a life sciences company specializing in the development and supply of critical reagents and services for the development and manufacture of biologic therapies. The company’s offerings support a range of applications in genomics, molecular diagnostics, vaccine development and next-generation sequencing. Maravai’s platforms address key challenges in nucleic acid production, protein detection, epigenetic analysis and reagent quality across the biopharmaceutical industry.

Through its product portfolio, which includes proprietary mRNA capping reagents, lipid nanoparticle delivery systems, synthetic oligonucleotides and high-precision assay kits, Maravai enables customers to accelerate research and streamline manufacturing workflows.